MedTrust Online Brings MICROMEDEX(R) DRUGDEX(R) From Thomson Reuters to Over 7,000 Online Oncologists

SCOTTSDALE, Ariz., Feb. 25 /PRNewswire/ -- MedTrust Online (www.medtrust-online.com), a leading provider of information-based solutions for oncologists treating difficult cancers, has made MICROMEDEX DRUGDEX® available to registered users of its Internet portal, Oncocentric.com.  

DRUGDEX® is the most comprehensive source of referenced drug information for evidence-based practice and a recognized standard for drug utilization review and screening. It enhances the clinical utility of Oncocentric.com for doctors seeking the right therapy for their cancer patients.

"This collaboration with Thomson Reuters provides our users with another critical source of clinical information about FDA-approved and investigational cancer drugs in an efficient electronic format accessible anytime through Oncocentric," said Leo Otake, M.D., Ph.D., Vice President of Medical Informatics for MedTrust Online.  "Simply put, our end users can find answers quickly as they are seeing patients and make informed decisions with more confidence that their therapy choices are clinically supported."

Users of Oncocentric™ can access and search the latest peer-reviewed literature, browse proprietary databases of similar difficult case presentations, identify pertinent clinical trials and molecular diagnostic tests, and confirm working hypotheses with their peers and with experts in oncology.  DRUGDEX® provides additional validation of clinicians' chosen treatments from a recognized reference standard for Medicare Parts B and D and for Medicaid.

"Through this initiative, more doctors will have access to a trusted source of clinically useful content," stated Tammy Williams, director of product management, Thomson Reuters.  "We are pleased to provide our information resources to oncologists through MedTrust Online's portal."

"DRUGDEX® adds another important resource to Oncocentric.com, further enabling our over 7,000 oncology professionals to access relevant, timely, and trusted information," stated Chris Yoo, Ph.D., President and CEO of MedTrust Online.  "We continue to provide the best information-based tools to help physicians save time and make the most informed therapeutic decisions."

About MedTrust Online, LLC

MedTrust Online LLC, www.medtrust-online.com, headquartered in Scottsdale, Arizona, provides oncologists with clinically useful technology applications and solutions. MedTrust Online brings together experts in oncology, information technology, computational biology, pharmaceutical drug development, and personalized medicine to capture, organize, analyze, integrate and present the most up-to-date medical facts from a vast array of sources. This data is provided to doctors in a comprehensive yet concise way unavailable anywhere else.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information to better manage the cost and quality of healthcare and accelerate scientific research and innovation. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto Stock Exchange (TSX: TRI) and New York Stock Exchange (NYSE: TRI). For more information, go to www.thomsonreuters.com

SOURCE MedTrust Online LLC